for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Precipio Inc

PRPO.OQ

Latest Trade

2.19USD

Change

0.00(0.00%)

Volume

76,091

Today's Range

2.04

 - 

2.27

52 Week Range

0.55

 - 

8.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.19
Open
2.16
Volume
76,091
3M AVG Volume
88.01
Today's High
2.27
Today's Low
2.04
52 Week High
8.00
52 Week Low
0.55
Shares Out (MIL)
16.43
Market Cap (MIL)
38.44
Forward P/E
-2.09
Dividend (Yield %)
--

Next Event

Q3 2020 Precipio Inc Earnings Release

Latest Developments

More

Precipio Inc Files For Offering 4.5 Million Shares Of Common Stock By Selling Stockholder

Precipio Files For Mixed Shelf Of Up To $50.0 Million - SEC Filing

Precipio Files For Offer And Sale Of Up To 1.8 Mln Shares Of Common Stock By The Selling Stockholder - SEC Filing

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Precipio Inc

Precipio, Inc. is a cancer diagnostics company providing diagnostic products and services to the oncology market. The Company’s platform is designed to provide physicians and their patients access to necessary technology in order to provide diagnoses. The Company is focused on developing various technologies including IV-Cell, HemeScreen and ICE-COLD-PCR (ICP). The IV-Cell is a proprietary culture media that addresses the problem of selective culturing-by creating a universal media that enables simultaneous culturing of hematopoietic cell lineages. ICP is a specimen enrichment technology that increases the sensitivity of molecular based tests. The Company has developed a screening panel for genes in one rapid scanning panel, HemeScreen.

Industry

Scientific & Technical Instr.

Contact Info

12325 Emmet St

OMAHA, NE

68164-4243

United States

+1.203.7877888

http://www.precipiodx.com/

Executive Leadership

Douglas Fisher

Interim Chairman of the Board

Ilan Danieli

President, Chief Executive Officer, Director

Carl R Iberger

Chief Financial Officer

Douglas Sites

Vice President - Sales

Ori Joseph Karev

Chief Strategy Officer

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019

0.0K

2020(E)

0.0K
EPS (USD)

2019

-2.330

2020(E)

-1.060
Price To Earnings (TTM)
--
Price To Sales (TTM)
9.62
Price To Book (MRQ)
2.71
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
9.36
LT Debt To Equity (MRQ)
5.92
Return on Investment (TTM)
-69.92
Return on Equity (TTM)
-53.91

Latest News

Latest News

BRIEF-Precipio Inc Files For Offering 4.5 Million Shares Of Common Stock By Selling Stockholder

* PRECIPIO INC FILES FOR OFFERING 4.5 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDER - SEC FILING Source text: [ID:https://bit.ly/31VeXeg] Further company coverage:

BRIEF-Precipio Regains Listing Compliance With Nasdaq Minimum Bid Requirement

* PRECIPIO REGAINS LISTING COMPLIANCE WITH NASDAQ MINIMUM BID REQUIREMENT Source text for Eikon: Further company coverage:

BRIEF-Precipio Inc Files For Potential Sale Of 4.5 Mln Shares Of Common Stock By Selling Stockholders

* PRECIPIO INC FILES FOR POTENTIAL SALE OF 4.5 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source text: [https://bit.ly/2Vp82pA] Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Precipio Files For Mixed Shelf Of Up To $50.0 Million - SEC Filing

* PRECIPIO INC FILES FOR MIXED SHELF OF UP TO $50.0 MILLION - SEC FILING

BRIEF-Precipio Files For Offer And Sale Of Up To 1.8 Mln Shares Of Common Stock By The Selling Stockholder - SEC Filing

* PRECIPIO INC FILES FOR OFFER AND SALE OF UP TO 1.8 MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDER - SEC FILING Source :(https://bit.ly/3dsRe8C) Further company coverage:

BRIEF-Precipio Enters Into Purchase Agreement With Lincoln Park Capital Fund, Llc

* PRECIPIO INC - ON MARCH 26, ENTERED INTO PURCHASE AGREEMENT WITH LINCOLN PARK CAPITAL FUND, LLC

BRIEF-Precipio Announces "Accelerating" Sales Of Its Pathology Services In April

* PRECIPIO INC - ACCELERATING SALES OF ITS PATHOLOGY SERVICES IN APRIL, INDICATING ANTICIPATED SEQUENTIAL DOUBLE DIGIT QUARTERLY SALES GROWTH

BRIEF-Precipio Launches Ice Cold-Pcr™ Liquid Biopsy Kit For Pancreatic Cancer

* PRECIPIO LAUNCHES ICE COLD-PCR™ LIQUID BIOPSY KIT FOR PANCREATIC CANCER

BRIEF-Precipio Inc Files For Non-Timely 10-Q

* PRECIPIO INC FILES FOR NON-TIMELY 10-Q WITH U.S. SEC Source http://bit.ly/2IJcN8g Further company coverage:

BRIEF-Precipio In Strategic Partnership Discussions For Proprietary Cytogenetics Media IV-Cell

* PRECIPIO IN STRATEGIC PARTNERSHIP DISCUSSIONS FOR PROPRIETARY CYTOGENETICS MEDIA IV-CELL

BRIEF-Precipio - Responses To Articles, On Its Approach Using Ice Cold-Pcr Liquid Biopsy Tests On Real Time Pcr Platforms

* PRECIPIO - RESPONSES TO ARTICLES, ON ITS APPROACH USING ICE COLD-PCR LIQUID BIOPSY TESTS ON REAL TIME PCR PLATFORMS Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Precipio - Announces Laboratory Services Agreement With Core Diagnostics

* PRECIPIO - ANNOUNCES LABORATORY SERVICES AGREEMENT WITH CORE DIAGNOSTICS FOR ICE COLD-PCR LIQUID BIOPSY TESTING SERVICES IN INDIA, OTHER ASIAN COUNTRIES

BRIEF-Precipio Restructures Capitalization Table

* PRECIPIO INC - TO CONVERT THEIR PREFERRED SHARES AND EXERCISE A SUBSTANTIAL PORTION OF THEIR WARRANTS Source text for Eikon: Further company coverage:

BRIEF-Precipio Settles Lawsuit With Crede Capital

* PRECIPIO INC - AS PART OF SETTLEMENT, PRECIPIO WILL PAY TO CREDE A TOTAL OF $1.925 MILLION OVER A PERIOD OF 15 MONTHS

BRIEF-Precipio Says On Feb 20, Crede Capital Group Filed Lawsuit In U.S. Court Against Co In Lieu Of Complaint Requiring Co To Pay Cash Owed To Crede - SEC Filing

* PRECIPIO SAYS ON FEB 20, CREDE CAPITAL GROUP FILED LAWSUIT IN U.S. COURT AGAINST CO IN LIEU OF COMPLAINT REQUIRING CO TO PAY CASH OWED TO CREDE - SEC FILING Source text: (http://bit.ly/2ozFadc) Further company coverage:

BRIEF-Precipio Launches Unique Lung Cancer Monitoring Test For Therapy Resistance

* PRECIPIO LAUNCHES UNIQUE LUNG CANCER MONITORING TEST FOR THERAPY RESISTANCE

BRIEF-Precipio Reports Q4 Revenue $945,000

* PRECIPIO ANNOUNCES Q4 2017 REVENUE AT 350% OF PREVIOUS QUARTER

BRIEF-Precipio Enters Into A Purchase Agreement With Leviston Resources

* PRECIPIO SAYS ON FEB 8, CO ENTERED INTO A PURCHASE AGREEMENT WITH LEVISTON RESOURCES TO BUY UP TO $8 MILLION OF SHARES OF CO'S S COMMON STOCK - SEC FILING

BRIEF-Precipio Q3 sales fell 26 percent

* Precipio announces third quarter 2017 financial results and provides corporate update

BRIEF-Precipio Inc files for non-timely 10-Q

* Precipio Inc files for non-timely 10-Q - SEC filing Source text: (http://bit.ly/2yyJYDg) Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up